Multiple Myeloma Posts - Page 6 of 27 on Medivizor

Evaluating outcomes of daratumumab, pomalidomide, and dexamethasone followed by high dose chemotherapy and ASCT for unresponsive multiple myeloma.

Posted by Medivizor on Apr 4, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study aimed to investigate the effectiveness of DPd (daratumumab, pomalidomide, and dexamethasone) as salvage therapy followed by high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) for relapsed/refractory (RR) multiple myeloma (MM). The study concluded that this therapy is effective and well tolerated...

Is lenalidomide a good choice as maintenance treatment in multiple myeloma?

Posted by Medivizor on Mar 28, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study examined whether multiple myeloma (MM) can become resistant to lenalidomide (Revlimid) when this drug is used as maintenance therapy (MT) after bone marrow transplant. The authors found that using lenalidomide when the cancer came back after lenalidomide MT was not associated with resistance and improved...

Evaluating factors associated with improved denosumab outcomes of patients with multiple myeloma

Posted by Medivizor on Mar 21, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated factors associated with improved outcomes of denosumab (Xgeva) compared to zoledronic acid (Zometa). The authors found that denosumab increased survival without cancer worsening in patients that planned to have an autologous stem cell transplant (ASCT) or those who previously received...

Evaluating the health-related quality of life in patients with multiple myeloma treated with daratumumab combined with bortezomib and dexamethasone.

Posted by Medivizor on Mar 21, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the health-related quality of life (HRQoL) for patients with relapsed/refractory (RR) multiple myeloma (MM) patients treated with D-Vd (daratumumab, bortezomib, and dexamethasone) compared to Vd (bortezomid and dexamethasone). The study showed that HRQoL did not decrease for 8 therapy cycles and long-term...

Is autologous stem cell transplant safe and effective for patients aged 75 or older with multiple myeloma?

Posted by Medivizor on Mar 6, 2021 in Multiple Myeloma | 0 comments

In a nutshell The aim of this study was to evaluate the safety and effectiveness of autologous stem cell transplant (ASCT) in patients with multiple myeloma (MM) aged 75 or older. The study found that ASCT was safe and effective for certain patients in this age group. Some background MM is a type of blood cancer that impacts bone marrow. Therapy for...

Is CAR-T-cell therapy targeting BCMA safe and effective for patients with multiple myeloma?

Posted by Medivizor on Mar 6, 2021 in Multiple Myeloma | 0 comments

In a nutshell The aim of this study was to evaluate the safety and effectiveness of a type of chimeric antigen receptor (CAR)-T-cell therapy that targets B-cell maturation antigens (BCMA) for patients with multiple myeloma (MM). The study found that patients had a very good response to therapy, while there was a high risk of side...

Evaluating carflizomib, lenalidomide, dexamethasone, and cyclophosphamide for newly diagnosed transplant-eligible patients with multiple myeloma.

Posted by Medivizor on Feb 28, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study compared a combination therapy of carfilzomib (Kyprolis), lenalidomide (Revlimid), dexamethasone (Decadron), and cyclophosphamide (Cytoxan) to control combination therapies as an alternative treatment regimen in newly diagnosed patients with multiple myeloma (MM). The authors concluded that this regimen provided very good...

Improved outcomes for relapsed/refractory multiple myeloma patients treated with daratumumab.

$Improved outcomes for relapsed/refractory multiple myeloma patients treated with daratumumab.$

Posted by Medivizor on Feb 27, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effect of daratumumab (Darzalex)-based treatments on sustained minimal residual disease (MRD) negativity and outcomes in patients with relapsed/refractory (RR) multiple myeloma (MM). The data showed that treatments including daratumumab led to sustained MRD negativity and improved outcomes in these...

How do bortezomib, thalidomide, dexamethasone and daratumumab impact the quality of life of patients with multiple myeloma?

Posted by Medivizor on Feb 26, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the health-related quality of life of patients with multiple myeloma (MM) after treatment with VTd (bortezomib, thalidomide, and dexamethasone) with or without daratumumab (D; Darzalex). The study found that all patients that received treatment had an improved quality of life, while...

Long-term follow-up after bortezomib, thalidomide, and dexamethasone treatment followed by double stem cell transplant in patients with multiple myeloma.

Posted by Medivizor on Feb 21, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study compared long-term outcomes after treatment with bortezomib (Velcade), thalidomide (Thalomid), and dexamethasone (Ozurdex) or VTD compared to thalidomide and dexamethasone (TD) followed by double hematopoietic stem cell transplant (HSCT) in patients with newly diagnosed multiple myeloma (MM). The study found...

Can low body mass index and undernutrition influence survival in patients with multiple myeloma?

Posted by Medivizor on Feb 14, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the impact of low body mass index (BMI; a measure of weight in relation to height) and undernutrition in patients with multiple myeloma (MM). The authors concluded that being underweight, low protein level higher high lactate dehydrogenase (LDH) and light chain ratios, and poor performance status were...

Comparing two ways of collecting stem cells to improve treatment of multiple myeloma

Posted by Medivizor on Feb 7, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study looked at two different ways of getting stem cells from the blood to improve the treatment of patients with multiple myeloma (MM). This study showed that the use of cyclophosphamide (CTX; Cytoxan) with granulocyte-colony stimulating factor (G-CSF; Neupogen) had the best outcomes. Some background MM is the second...

Multiple Myeloma Posts on Medivizor

Evaluating outcomes of daratumumab, pomalidomide, and dexamethasone followed by high dose chemotherapy and ASCT for unresponsive multiple myeloma.

Is lenalidomide a good choice as maintenance treatment in multiple myeloma?

Evaluating factors associated with improved denosumab outcomes of patients with multiple myeloma

Evaluating the health-related quality of life in patients with multiple myeloma treated with daratumumab combined with bortezomib and dexamethasone.

Is autologous stem cell transplant safe and effective for patients aged 75 or older with multiple myeloma?

Is CAR-T-cell therapy targeting BCMA safe and effective for patients with multiple myeloma?

Evaluating carflizomib, lenalidomide, dexamethasone, and cyclophosphamide for newly diagnosed transplant-eligible patients with multiple myeloma.

Improved outcomes for relapsed/refractory multiple myeloma patients treated with daratumumab.

How do bortezomib, thalidomide, dexamethasone and daratumumab impact the quality of life of patients with multiple myeloma?

Long-term follow-up after bortezomib, thalidomide, and dexamethasone treatment followed by double stem cell transplant in patients with multiple myeloma.

Can low body mass index and undernutrition influence survival in patients with multiple myeloma?

Comparing two ways of collecting stem cells to improve treatment of multiple myeloma

Categories

Recent Posts

Archives

Multiple Myeloma Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email